IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?
@article{Rodrigues2005IMPACTOC, title={IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?}, author={A. David Rodrigues}, journal={Drug Metabolism and Disposition}, year={2005}, volume={33}, pages={1567 - 1575} }
The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in vitro. This observation has led some to hypothesize that a reduction in clearance…
Tables from this paper
105 Citations
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
- Biology, MedicinePharmacogenomics
- 2009
Clinical data regarding the impact of the CYP2C8*3 allele on the disposition of NSAIDs are conflicting and no definitive conclusions can be made at this time, but contrary to in vitro data, clinical data suggest that the CYC2C48*2 and *3 allele is associated with increased metabolism of the cytochrome P450 substrates, rosig litazone, pioglitazone and repaglinide.
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
- Biology, MedicineToxicology
- 2010
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
- Biology, MedicineJournal of personalized medicine
- 2017
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism. Polymorphisms resulting in decreased enzyme activity are…
The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs
- Biology, MedicineClinical pharmacokinetics
- 2007
The traditional and validated therapeutic drug monitoring approach, representing a direct ‘phenotype’ assessment, still remains the method of choice when an individualised dosing regimen is anticipated, but pharmacogenetics and pharmacogenomics can offer some novel contributions when attempts are made to maximise drug efficacy and enhance drug safety.
Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?
- Medicine, BiologyClinical pharmacology and therapeutics
- 2006
Pharmacogenetics of non-steroidal anti-inflammatory drugs: existing problems for clinical practice
- Medicine, BiologyMedical Council
- 2019
The pharmacogenetic predictors of adverse effects that patients can experience, and the need for dose adjustment based on the patient’s genotype, or individualizing the choice of alternative NSAIDs to increase the effectiveness of analgesia, have been determined.
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
- Medicine, BiologyGastroenterology
- 2007
CYP2C9 genotyping may identify subgroups of persons who potentially are at increased risk of gastroduodenal bleeding when treated with NSAIDs metabolized by CYP2C8, and further studies that evaluate the effectiveness of a strategy using CYP 2C9genotyping in NSAID users are needed.
Clinical pharmacology of celecoxib, a COX-2 selective inhibitor
- MedicineExpert opinion on pharmacotherapy
- 2007
It could be suggested that the use of low doses of celecoxib in short-treatment, especially in patients with previous experience of GI events, contribute in the decision-making process of prescribing COX-2 or NSAIDs.
Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
- BiologyDrug metabolism and drug interactions
- 2014
In the present review, functional changes of all known CYP2C9 protein coding alleles were predicted using in silico analyses and compared with the in vitro and in vivo data.
Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
- Medicine, BiologyBasic & clinical pharmacology & toxicology
- 2011
The half-life, oral clearance and AUC(inf) of lornoxicam were similar in individuals with CYP2C9*1/*13 and those with CYp2C 9*1*3, although C(max) was higher in CYP1*1*/13 individuals, and a CYP3*1 /*3 genotype markedly reduced the conversion of lORNoxicam to 5'-hydroxylorn Toxicam.
References
SHOWING 1-10 OF 145 REFERENCES
CYP2C9 genotype as a predictor of drug disposition in humans.
- BiologyMethods and findings in experimental and clinical pharmacology
- 2004
Findings suggest that CYP2C9 genotype-guided dosing may be clinically useful and warrants prospective investigation.
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
- Medicine, ChemistryPharmacogenetics
- 2003
In-vitro data indicate major effects of the genetically polymorphic cytochrome P450 enzyme 2C9 (CYP2C9) on the pharmacokinetics of celecoxib, a nonsteroidal anti-inflammatory drug acting as selective…
Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.
- Biology, MedicineCurrent drug metabolism
- 2002
Current trends in the industry have been fueled by increased managed healthcare, the desire to minimize the need for therapeutic drug monitoring and CYP genotyping in medical practice, and a very competitive market place.
Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient
- Medicine, BiologyClinical pharmacology and therapeutics
- 2005
Clinical Consequences of Cytochrome P450 2C9 Polymorphisms
- Biology, MedicineClinical pharmacology and therapeutics
- 2005
Pharmacokinetics of Rofecoxib
- Medicine, BiologyClinical pharmacokinetics
- 2003
COX-2 inhibitors represent a major therapeutic advance in terms of gastrointestinal safety; however, long-term safety in other organ systems and with concomitant drug administration still remain to be proven.
Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance
- BiologyClinical pharmacology and therapeutics
- 2005
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
- Biology, MedicineBritish journal of clinical pharmacology
- 1998
Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates.
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.
- BiologyAnnual review of pharmacology and toxicology
- 2005
New, ultrapotent inhibitors of CYP2C9 have been synthesised that aid in the development of quantitative structure-activity relationship (QSAR) models to facilitate drug redesign, and extensive resequencing of the gene and studies of its regulation will undoubtedly help to understand interindividual variability in drug response and toxicity controlled by this enzyme.
Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.
- Medicine, BiologyBritish journal of clinical pharmacology
- 2005
The results show that the pharmacokinetics of lornoxicam are dependent on CYP2C9 polymorphism, and the presence of the CYP1C9*3 allele impairs the oral clearance of lORNoxicam.